Challenges and strategies of non-coding RNA therapies in addressing tumor heterogeneity in head and neck cancers.

Head and neck cancers (HNCs) are characterized by substantial genetic, epigenetic, transcriptional, and microenvironmental heterogeneity, which contributes to variable responses and limited durability of non-coding RNA (ncRNA)-based therapies. Although previous reviews have extensively catalogued dysregulated miRNAs, lncRNAs, and circRNAs in HNC, less attention has been paid to how tumor heterogeneity dynamically reshapes ncRNA-target relationships and therapeutic responses. Here, we introduce heterogeneity-driven target drift as a conceptual framework linking multidimensional tumor heterogeneity to ncRNA therapeutic instability. We first examine the molecular mechanisms by which genetic variation, alternative polyadenylation, epigenetic remodeling, viral status, and the tumor microenvironment shape heterogeneous ncRNA functions. We then analyze three major translational barriers: heterogeneous drug delivery, context-dependent target engagement, and microenvironmental interference and resistant subclones. Finally, we discuss actionable precision strategies, including heterogeneity-informed diagnostics, targeted and stimuli-responsive delivery, CRISPR-based ncRNA editing, intercellular therapeutic circuits, APA-directed interventions, and multimodal combinations. We propose a heterogeneity-aware framework integrating dynamic molecular profiling, individualized target selection, adaptive treatment design, and clinically scalable delivery to improve the predictability and durability of ncRNA therapies in HNC.